Dr. Farn H. Chan

Scott Rowley is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Rowley is rated as an Elite provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Colonoscopy.

Danielle Shafer is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Shafer is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Myringotomy. Dr. Shafer is currently accepting new patients.

Dr. B. Douglas Smith is an Oncologist in Baltimore caring for patients with leukemias and other blood and bone marrow disorders and he is recognized nationally as an expert in the care of patients with these disorders and as a leader in novel therapeutics for these conditions. Dr. Smith serves as the Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies and helps to manage the Division’s clinical research trials. Dr. Smith received his undergraduate degree in Biology from Lafayette College (Easton, PA), earned his M.D. at the Medical College of Pennsylvania (Philadelphia, PA), completed his Residency at Strong Memorial Hospital of the University of Rochester (Rochester, NY), and Fellowship in Medical Oncology at Johns Hopkins (Baltimore, MD). Dr. Smith joined the Johns Hopkins faculty in 1998 at the completion of his training. His main research interests include drug development for patients with AML, CML, and MDS and he serves as Co-Investigator for the Oncology Center’s UM1 (early phase drug development) Grant. The Leukemia Program’s clinical trials portfolio has included trials for each of the 8 newly FDA-approved drugs for acute leukemia in the past 2 years. Dr. Smith has a passion for teaching trainees and has served on the Fellowship Executive Committee since 2010 focusing on the program’s educational platforms. He has won numerous teaching awards in both the Department of Oncology and the Department of Medicine multiple times, and he has a track record of mentoring fellows pursuing clinical-translational research and clinician-educator pathways. In 2020, Dr. Smith was awarded membership in the prestigious Miller Coulson Academy for Excellence in Clinical Care. He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Association for Cancer Research. He has served on the National Comprehensive Cancer Network guideline panel for CML since 2001 and previously served on the AML panel from 2001-2015. Dr. Smith has extensive experience in the regulatory aspects of drug development and he currently serves as the Chair of the Johns Hopkins Institutional Review Board #2. Dr. Smith is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Childhood Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.